120 related articles for article (PubMed ID: 6572569)
1. Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion.
Slevin ML; Piall EM; Aherne GW; Johnston A; Lister TA
Cancer Chemother Pharmacol; 1983; 10(2):112-4. PubMed ID: 6572569
[TBL] [Abstract][Full Text] [Related]
2. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
3. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
Slevin ML; Piall EM; Aherne GW; Johnston A; Sweatman MC; Lister TA
Br J Clin Pharmacol; 1981 Oct; 12(4):507-10. PubMed ID: 6945865
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.
Groothuis DR; Benalcazar H; Allen CV; Wise RM; Dills C; Dobrescu C; Rothholtz V; Levy RM
Brain Res; 2000 Feb; 856(1-2):281-90. PubMed ID: 10677637
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of low-dose cytosine arabinoside.
Spriggs D; Griffin J; Wisch J; Kufe D
Blood; 1985 May; 65(5):1087-9. PubMed ID: 3995167
[TBL] [Abstract][Full Text] [Related]
7. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension.
Slevin ML; Piall EM; Johnston A; Levison DA; Aherne GW; Tree SB; Lister TA
Invest New Drugs; 1984; 2(3):271-6. PubMed ID: 6511233
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside.
Weinstein HJ; Griffin TW; Feeney J; Cohen HJ; Propper RD; Sallan SE
Blood; 1982 Jun; 59(6):1351-3. PubMed ID: 7082832
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
11. Technique for preclinical evaluation of continuous infusion chemotherapy with the use of WF rat acute myelogenous leukemia.
Ensminger WD; Greenberger JS; Egan EM; Muse MB; Moloney WC
J Natl Cancer Inst; 1979 May; 62(5):1265-8. PubMed ID: 155752
[TBL] [Abstract][Full Text] [Related]
12. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
[TBL] [Abstract][Full Text] [Related]
13. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
[TBL] [Abstract][Full Text] [Related]
15. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.
Griffin JD; Spriggs D; Wisch JS; Kufe DW
J Clin Oncol; 1985 Jul; 3(7):982-91. PubMed ID: 4020409
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
Vazquez Fuster IB; Taylor AR; Smith AN; Duran SH; Ravis WR; Jasper SL; Arnold RD
J Vet Intern Med; 2020 Jul; 34(4):1563-1569. PubMed ID: 32442344
[TBL] [Abstract][Full Text] [Related]
17. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
18. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
[TBL] [Abstract][Full Text] [Related]
20. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
Wiley JS; Jones SP; Sawyer WH; Paterson AR
J Clin Invest; 1982 Feb; 69(2):479-89. PubMed ID: 6948829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
